M. Wang Et Al. , "Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).," Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , ELECTR NETWORK, 2022
Wang, M. Et Al. 2022. Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , (ELECTR NETWORK).
Wang, M., Jurczak, W., Jerkeman, M., Trotman, J., Zinzani, P. L., Walewski, J. A., ... Zhu, J.(2022). Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL). . Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK
Wang, Michael Et Al. "Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).," Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022
Wang, Michael Et Al. "Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , ELECTR NETWORK, 2022
Wang, M. Et Al. (2022) . "Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , ELECTR NETWORK.
@conferencepaper{conferencepaper, author={Michael Wang Et Al. }, title={Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).}, congress name={Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)}, city={}, country={ELECTR NETWORK}, year={2022}}